Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$8.30
-$0.02(-0.18%)
At close: 4:00 PM EST
$8.30
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.63
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.77M
Market Cap
$695.12M
Enterprise Value$1.06B
Total Cash (Recent Filing)$200.97M
Total Debt (Recent Filing)$96.52M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding99,303,260
10 Day Avg. Volume1,551,220
30 Day Avg. Volume1,774,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue10.66
Enterprise Value/Gross Profit13.83
Enterprise Value/Ebitda-5.49
Forecast
1Y Price Target
$30.00Price Target Upside261.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$141.74M
Bulls Say, Bears Say
Bulls Say
Product-level EconomicsHigh gross margins (~75.8%) with mid-teens TTM revenue growth indicate attractive unit economics that can sustain profitability as volumes scale. Durable product-level profitability reduces reliance on pricing upside and supports long-term margin expansion as gross-to-net stabilizes.
Commercial Traction And AdoptionRapid prescription and patient-base growth (3x YoY; ~120k patients) show durable market adoption and repeat prescribing behavior. A growing installed base creates predictable refill revenue over time, improving visibility into demand and supporting long-term commercial scalability.
Regulatory And International ExpansionRegulatory approvals (FDA label expansion, Health Canada, EC authorization) materially broaden addressable markets and reduce regulatory uncertainty. International partner launches and pediatric label expansion create multi-market growth levers that persist beyond short-term seasonality.
Bears Say
High Cash BurnSustained negative operating cash flow (~-$175M TTM) signals ongoing funding needs; absent durable operating cash generation this creates dilution or financing risk. Cash burn weakens runway assumptions and makes strategic choices (marketing, R&D) dependent on external capital.
Elevated Operating SpendVery high SG&A tied to commercialization increases the time and sales volume required to reach profitability. Persistent elevated spend raises execution risk: if refill maturation or payer wins lag, fixed commercial costs will prolong losses and pressure margins over multiple quarters.
Access Friction And AbandonmentMaterial prescription abandonment (~22–23%) and prior-authorization barriers limit conversion of written scripts into sustained refill revenue. These structural access frictions slow refill maturation, reduce lifetime patient value, and make revenue timing and predictability dependent on external payer decisions.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $6.66 and its highest was $18.63 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $695.12M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on May 15, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.516 by -$0.094.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,303,260 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.516. Following the earnings report the stock price went down -6.486%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (261.45% Upside)
$30.00 (261.45% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 339.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.14%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
SPRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress (robust YoY prescription and revenue growth, regulatory approvals, expanded coverage and new affordability programs), backed by a healthy cash balance and a clear plan to scale through the back-to-school season and refill cycles. However, execution risks remain: significant SG&A spend and cash burn, prior-authorization friction that still limits access for a meaningful portion of covered lives, notable prescription abandonment, and uncertainty around timing of key payer decisions (e.g., CVS Caremark). On balance, the positives around growth, access expansion, regulatory wins and commercial initiatives outweigh the operational challenges, but the company remains execution- and timing-dependent over the coming quarters.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$30.00
▲(261.45% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
50.06% Insiders
6.93% Mutual Funds
1.04% Other Institutional Investors
32.57% Public Companies and
Individual Investors